Transfusion-dependent Iron Overload
📧 Sign up to get email alerts when something new happens for Transfusion-dependent Iron Overload.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-03-05FDA Approved: DEFERASIROX — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for deferasirox from Zydus Pharmaceuticals USA Inc., updating the product labeling.
-
FDA approval · 2020-07-02FDA Approved: DEFERASIROX — Original Application (Ascend Laboratories, LLC)
FDA approved the original ANDA for a generic deferasirox (DEFERASIROX) from Ascend Laboratories, expanding access to an iron-chelating thera…
-
FDA approval · 2020-06-15FDA Approved: DEFERASIROX — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal's generic deferasirox (Deferasirox) as an original ANDA for the treatment of transfusion-related iron overload in pa…
-
FDA approval · 2020-06-15FDA Approved: DEFERASIROX — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves a generic version of deferasirox (Zydus Pharmaceuticals USA) under ANDA211383 for chronic iron overload due to blood transfusio…
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload [Phase 3]
Phase 3 trial updating efficacy and safety of Deferasirox in patients with transfusion-dependent iron overload (completed).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-12-30FDA Approved: DEFERASIROX — Original Application (Xiromed, LLC)
FDA approved Xiromed, LLC's generic deferasirox (DEFERASIROX) through an original ANDA.
-
FDA approval · 2019-11-20FDA Approved: DEFERASIROX — Original Application (Alembic Pharmaceuticals Limited)
FDA approved a generic version of deferasirox (DEFERASIROX) from Alembic Pharmaceuticals Limited under an Original Application for the treat…
-
FDA approval · 2018-12-12FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Exjade (deferasirox) by Novartis, expanding the labeling for treating chronic iron overload due …
-
CLINICAL_TRIALS trial_result · 2017-05-31Clinical Trial Update: Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload [Phase 4]
Phase 4 trial assessing the efficacy and safety of deferasirox in patients with myelodysplastic syndrome and transfusion-dependent iron over…
-
CLINICAL_TRIALS trial_result · 2011-08-11Clinical Trial Update: Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study [Phase 2, Phase 3]
A non-comparative extension trial assesses safety and efficacy of deferasirox in transfusion-dependent iron overload with liver involvement;…
-
FDA label_change · 2007-12-21FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for EXJADE (deferasirox) by Novartis Pharmaceuticals Corporation, updating the product labeling.